Cipla reports Q4 FY 23 consolidated PAT at Rs. 525.65 Cr
Cipla has reported total income of Rs. 5873.93 crores during the period ended March 31, 2023
Cipla has reported total income of Rs. 5873.93 crores during the period ended March 31, 2023
The company has reported total income of Rs. 187.75 crores during the period ended March 31, 2023
This decision will accelerate growth for both its pharma & consumer healthcare businesses in India
Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time
Acquisition of XinThera provides Gilead with precision small molecules focused on PARP1 and MK2 Inhibitors
The company has reported total income of Rs. 211.62 crores during the period ended March 31, 2023
Sunrise is built on four elements i.e., Awareness, Screening & Diagnosis, Treatment, and Maintenance Support
Pandemic was the opportunity for Ayush to develop their science and Ayush did it by developing Ayush 64, etc
Wider reach for nutraceuticals portfolio in Europe, Turkey and Egypt
The company has reported total income of Rs. 4467.35 crores during the quarter ended March 31, 2023
Subscribe To Our Newsletter & Stay Updated